Today on Drug Discovery & Development
FDA greenlights Jesduvroq, which GSK hails as ‘first innovative medicine’ for anemia in three decades
GSK (NYSE:GSK) has received FDA approval for Jesduvroq, an oral oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a daily treatment for anemia associated with chronic kidney disease in adult dialysis patients. Jesduvroq is the first new medicine for anemia treatment in over 30 years, GSK noted. The drug is the only HIF-PHI to win…
Community oncology groups driving more clinical trials
In the U.S., most cancer patients receive care in a community setting, a unique care model that traces its origins back to the original war on cancer. Since then, the National Cancer Institute and other organizations have supported this model of pushing more cancer care to community settings. Community oncology groups are poised to conduct a…
Drug Discovery and Development See More >
Big Pharma companies trimming pipelines in 2023
Several companies, including GSK, Janssen, Novartis and Pfizer, have announced that they are cutting their pipelines as they release their full-year 2022 financial results. The following are the drugs removed from these companies’ pipelines. Bristol Myers Squibb Anti-CTLA-4 NF: The oncology monoclonal antibody candidate directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) known as BMS-986218 was…
An overview of common drug types: biologics, small molecules and cell/gene therapy
A pandemic waiting to happen: Acute radiation syndrome and the immediate need for nuclear countermeasures
Lilly gets FDA review for empagliflozin in chronic kidney disease
Genascence believes gene therapy can transform the treatment of knee osteoarthritis
Sponsored Content See More >
Noble Leads with its User-Centered Design StrategyBy Tim McLeroy, Executive Director of Marketing and Patient Services, Noble International At Noble, the patient journey drives everything we…
Using Real-World Data to Address COVID-19By Cheryl Reifsnyder, PhD As a leading provider of data and advanced analytics, Veradigm understands the critical role real-world data…
Discovering Antigen-specific Monoclonal Antibodies using Single B Cell ScreeningIntroduction Since the approval of Orthoclone OKT3 in 1986, more than 100 monoclonal antibodies (mAbs) have been approved by the…
A new way to access scientific papers?Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to…
These are not fireworks: The objective truthBy Jan Barghaan, Strategic Marketing Manager Life Science, Olympus Europa No, not fireworks — it’s actually a single colony of…
AI technology automates tedious cell culture work and analysesBy Joanna Hawryluk, PhD, Product Manager, Olympus Life Science Since the early 20th century, cell culture has been considered the…
What is Human AB serum?By Trevor Smith, MS MBA, Product Manager, Immune Cells Human AB Serum is a staple in the biological research field,…
Resolving binding kinetics on a microplate readerWith a better understanding of the causes and mechanisms behind diseases arises a need for new treatment options and drugs…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
Proteomics can help us realize a future of precision healthcare: Takeaways from a 2023 prediction
Clinicians are ready and eager for the future of diagnostic and prognostic models — ones that are built on proteomics. I have been feeling and hearing one key theme in 2022 – physicians are ready, even dare I say eager, to get their hands on proteomic tests and tools that better empower and equip them…
Infectious Disease See More >
New study suggests link between Moderna COVID-19 booster and chronic hives
A Swiss study found that the monovalent Moderna (Nasdaq:MRNA) COVID-19 booster vaccine may be linked to a higher risk of a type of hives known technically as chronic spontaneous urticaria (CSU). In a cohort of the study based in the Swiss canton of Vaud, 90% of people who received the mRNA-based Moderna COVID-19 booster and developed…
Oncology See More >
Ymmunobio gets ownership rights to NPTXR antibodies
The biotech Ymmunobio has acquired ownership rights to neuronal pentraxin receptor (NPTXR) antibodies, which could promise in treating several gastrointestinal cancers. Basel, Switzerland–based Ymmunobio reached an agreement with Nagoya University in Japan in 2022 to transfer rights to the antibodies. Professor Mitsuro Kanda of Nagoya University invented the antibodies. A 2020 article published in Molecular…
Federated learning pact between Penn Medicine and Intel boosted glioblastoma detection capabilities
Genentech on how Lunsumio could shift the treatment landscape for R/R FL
Why the immunotherapy startup 3T Biosciences is working with Boehringer Ingelheim
